Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oragenics, a biopharmaceutical company, has announced that Stanley Stein has resigned as president, CEO and director of the company. Mr Stein will, however, continue to provide services as an advisor.
Subscribe to our email newsletter
Mr Stein’s resignation is not due to any disagreement with the company on any matter related to its operations, policies, and practices, the company said.
David Hirsch, the company’s CFO and COO, will assume additional responsibilities as acting CEO and Robert Zahradnik, the company’s vice president of business development, will assume the role of acting COO formerly served by Mr Hirsch.
Richard Welch, chairman of the board of Oragenics, said: “We look forward to continuing to work with Stan in certain select matters relating to strategic alternatives, business development and capital strategies. Also, the board is very confident that David Hirsch has the requisite skill sets to effectively lead the company at this time and continue to move things forward in a very exciting year for the company.”